Omada Teams Up With Lilly to Make Weight‑Loss Drugs Easier for Workplaces
Omada Health has teamed up with Eli Lilly’s Employer Connect program, stepping in as an independent manager of a new weight‑loss medication pathway. The partnership lets employers give employees access to the GLP‑1 Care Track, which covers medical checks, prescriptions and ongoing drug monitoring. This new route adds to Omada’s existing pharmacy‑benefit and cash‑pay options, giving employers a clearer way to bundle medication with lifestyle coaching.
How the Program Works
- Transparent Pricing: By working inside Lilly’s system, Omada can offer a clear price for Zepbound® and let companies set predictable contribution levels.
- Single Coordinated Program: Covers both the drug and the support needed to keep people on track.
- Three Main Options:
- Pharmacy‑benefit manager
- Direct‑to‑employer
- Cash‑pay
Employers can now choose the option that best matches their coverage design and workforce needs.
Why It Matters
- Growing Demand: Anti‑obesity medicines are in higher demand as budgets tighten.
- Patient Needs: Surveys of over 3,000 non‑Omada patients show a strong desire for more doctor time and extra diet/exercise help.
- Cost Concerns: Nearly half of respondents currently pay more than $250 a month out‑of‑pocket.
- Efficacy: Data suggest patients on GLP‑1 therapy for a year lose more weight and maintain it longer than usual.
Omada’s Integrated Approach
- Human Care Teams
- Connected Devices
- AI‑Powered Guidance
With 15 years of experience in virtual cardiometabolic care, Omada claims to have helped more than a million people improve health outcomes while keeping costs down. The Lilly partnership aims to give employers a sustainable way to support obesity treatment and help employees achieve lasting progress.
Bottom Line
This partnership expands the ways companies can provide weight‑loss support. It offers a clear cost structure for employers, more comprehensive care for patients, and a chance to keep people healthier in the long run.
